Last reviewed · How we verify
placebo glimepiride
Placebo glimepiride is an inert formulation containing no active pharmaceutical ingredient and produces no pharmacological effect.
At a glance
| Generic name | placebo glimepiride |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo, this formulation contains no glimepiride or other active drug substance. It is used as a control in clinical trials to assess the placebo effect and distinguish true drug efficacy from patient expectation or natural disease progression. Any observed clinical benefit would be attributable to placebo response rather than direct pharmacological action.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes (PHASE3)
- Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction. (PHASE3)
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients (PHASE3)
- Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes (NA)
- Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin (NA)
- Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy (PHASE2, PHASE3)
- Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |